Table 1 Patient characteristics and... | American Society of Hematology

Table 1

Patient characteristics and results of JAK2 V617F mutation detection

Patient no.	Sex/age at diagnosis, y	% RS	Maximum platelet count × 10⁹/L	Hb level, g/L	WBC count × 10⁹/L	Karyotype	Follow-up	JAK2 V617F by PCR	% Mutant DNA by sequencing
1804	M/84	15	1012	74	32.5	ND	Lost to follow-up	Positive	60
1693	F/87	45	942	91	17.0	ND	Deceased; 5 mo	Positive	45
900	F/59	43	999	109	8.9	Normal	Alive; 233 mo	Positive	30
2103	F/80	15	2100	52	20.3	ND	Deceased; 1 mo	Positive	30
2637	M/72	19	695	96	7.3	Normal	Alive; 10 mo	Positive	Negative
2644	F/63	57	664	73	2.9	Normal	Alive; 12 mo	Negative	Negative
G329	M/54	50	719	102	8.4	Normal	Alive; 118 mo	Positive	Negative
7574	F/72	35	1116	92	6.1	Normal	Alive; 50 mo	Positive	15
G372	F/65	50	684	104	16.9	del12p (1.1-1.3)	Alive; 5 mo	Positive	70
9853	M/54	50	773	144	10.5	Normal	Alive; 32 mo	Positive	75

Patient no.	Sex/age at diagnosis, y	% RS	Maximum platelet count × 10⁹/L	Hb level, g/L	WBC count × 10⁹/L	Karyotype	Follow-up	JAK2 V617F by PCR	% Mutant DNA by sequencing
1804	M/84	15	1012	74	32.5	ND	Lost to follow-up	Positive	60
1693	F/87	45	942	91	17.0	ND	Deceased; 5 mo	Positive	45
900	F/59	43	999	109	8.9	Normal	Alive; 233 mo	Positive	30
2103	F/80	15	2100	52	20.3	ND	Deceased; 1 mo	Positive	30
2637	M/72	19	695	96	7.3	Normal	Alive; 10 mo	Positive	Negative
2644	F/63	57	664	73	2.9	Normal	Alive; 12 mo	Negative	Negative
G329	M/54	50	719	102	8.4	Normal	Alive; 118 mo	Positive	Negative
7574	F/72	35	1116	92	6.1	Normal	Alive; 50 mo	Positive	15
G372	F/65	50	684	104	16.9	del12p (1.1-1.3)	Alive; 5 mo	Positive	70
9853	M/54	50	773	144	10.5	Normal	Alive; 32 mo	Positive	75

% RS indicates percentage of ringed sideroblasts in the bone marrow; WBC, white blood cell; and ND, not determined.